MARKET

BVXV

BVXV

Biondvax Pharmac
NASDAQ
9.87
+0.06
+0.66%
Closed 16:00 12/07 EST
OPEN
9.68
PREV CLOSE
9.81
HIGH
10.00
LOW
9.67
VOLUME
17.72K
TURNOVER
93.88K
52 WEEK HIGH
34.90
52 WEEK LOW
5.34
MARKET CAP
18.62M
P/E (TTM)
-0.3736
1D
5D
1M
3M
1Y
5Y
IBN (InvestorBrandNetwork) Coverage Initiated for BiondVax Pharmaceuticals Ltd.
LOS ANGELES, Dec. 06, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the tre...
GlobeNewswire · 1d ago
BRIEF-Matthias Dobbelstein Joins BiondVax's Scientific Advisory Board
Reuters · 1d ago
Professor Dr. Matthias Dobbelstein joins BiondVax’s Scientific Advisory Board
Professor Dr. med. Matthias Dobbelstein Professor Dr. med. Matthias Dobbelstein Jerusalem, Dec. 06, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing and c...
GlobeNewswire · 1d ago
BRIEF-Biondvax Announces Third Quarter 2022 Financial Results And Provides Business Update
Reuters · 11/30 14:43
BiondVax Announces Q3 2022 Financial Results And Provides Business Update; As of Sept. 30, 2022, BiondVax Had Cash And Cash Equivalents Of NIS29.4 Million ($8.3 Million) Compared To NIS54 Million YoY
Benzinga · 11/30 14:18
BRIEF-Biondvax Reports Results Of Preclinical Study for Inhaled Covid-19 Therapy
Reuters · 11/29 12:33
BiondVax Reports Results From Preclinical In Vivo Studies Of COVID-19 NanoAb Therapy
Benzinga · 11/29 12:07
BiondVax reports successful results in preclinical in vivo study of its innovative inhaled COVID-19 NanoAb therapy
Hamsters infected with SARS-COV-2 and then treated with inhaled anti-COVID-19 NanoAbs demonstrated significantly less severe illness and faster recovery in comparison to infected hamsters treated with inhaled placeboBiondVax’s nanosized antibodies (NanoAbs...
GlobeNewswire · 11/29 12:00
More
About BVXV
BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing and commercializing of innovative products for the prevention and treatment of infectious diseases but also for other illnesses. BiondVax Pharmaceuticals Ltd core focus is to develop of NanoAbs for treatment of COVID-19, psoriasis and asthma. Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally the Company offers manufacturing facility, aseptic fill and finish suite, laboratories and experienced professionals for other research and development companies. BiondVax Pharmaceuticals Ltd operates in Israel.

Webull offers kinds of Biondvax Pharmaceuticals Ltd - ADR stock information, including NASDAQ:BVXV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BVXV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BVXV stock methods without spending real money on the virtual paper trading platform.